ClinicalTrials.gg
RecruitingNCT06636162Updated May 6, 2026

Window of Opportunity Study of DSP-0390 in Gliomas

An Early Phase 1 interventional study of DSP-0390 in Glioma, Malignant and IDH Mutation, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Washington University School of Medicine · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Glioma by Washington University School of Medicine — 2 open to participants now, 4 under way, none of them phase 3. Glioma · Washington University School of Medicine.

Planned enrollment
6th of 13
20 · median 14
Started
2025
the only one that year
Phase 1
5 of 14
1 open now
Registered
13th of 14
by date

Among the 14 studies in Glioma by Washington University School of Medicine, this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 5 in phase 1, and was the 13th registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

2 of the 14 studies in Glioma by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Glioma by Washington University School of Medicine, or all of them as a file.
02

Study summary

This study focuses on determining the pharmacokinetic and pharmacodynamic effect of DSP-0390 in brain and blood from patients with IDH-mutant glioma undergoing tumor resection. Tissue will be collected during surgical resection. Blood will be drawn at various time points throughout the 2 weeks of treatment. The hypothesis is that DSP-0390 will accumulate in brain tumor tissue at pharmacologically relevant concentrations, and that alterations in cholesterol metabolism driven by mutant IDH will increase susceptibility to DSP-0390 and lead to tumor cell death.

03

Conditions studied

  • Glioma, Malignant
  • IDH Mutation

Keywords

  • DSP-0390
  • IDH-mutant glioma
  • brain tumor
  • brain cancer
  • low grade glioma
  • high grade glioma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have either newly diagnosed and suspected glioma per radiographic features, or radiographic recurrence of a confirmed IDH-mutant glioma with the following grade requirements:

    • ARM A: suspected lower grade glioma, or histologically confirmed grade II IDH-mutant glioma OR
    • ARM B: suspected high grade glioma, or histologically confirmed grade III or IV glioma.
  • Patient must be a candidate for surgical resection
  • At least 18 years of age.
  • ≥ 70%
  • Adequate bone marrow and organ function as defined below:

    • ≥ 1.5 K/cumm (patient may not use G-CSF or GM-CSF to achieve this ANC level)
    • ≥ 100 K/cumm
    • ≥ 9 g/dL (patient may not receive transfusion or use erythropoietin to obtain this Hgb level)
    • Total ≤ 1.5 x IULN (or ≤ 3 x IULN for patients with known Gilbert's syndrome)
    • (SGOT)/ALT(SGPT) ≤ 3.0 x IULN
    • (INR), prothrombin time (PT), partial thromboplastin time (PTT), or activated partial thromboplastin time (aPTT) ≤1.5 x . The use of anticoagulants is permitted as long as the PT/(a)PTT is within therapeutic limits (according to the local institution standard) and the patient has been on a stable anticoagulant regimen for at least 2 weeks prior to Day 1.
    • of ≥40 mL/min per Cockroft-Gault formula or by a 24 hour urine.
  • If a patient is using an antiepileptic medication, the patient is on a stable dose and without seizures for 14 days prior to Day 1. The antiepileptic medication used must not fall under any prohibited therapy category as defined in the protocol.
  • If the patient is receiving at baseline, the dose administered is stable or decreasing for at least 5 days prior to Day 1. A higher stable dose of corticosteroids, if used as hormone replacement therapy, may be allowed upon discussion with the sponsor-investigator.
  • The effects of DSP-0390 on the developing human fetus are unknown. For this reason, women of and men must agree to use adequate (2 forms of acceptable contraception, including one barrier method) prior to study entry, for the duration of study participation, and for 6 months after the last dose of DSP-0390. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
  • Ability to understand and willingness to sign an IRB approved written document.

Exclusion criteria

Exclusion Criteria

  • Patient has had prior therapy with bevacizumab or other anti-vascular endothelial growth factor (VEGF) treatments within 3 months prior to Day 1.
  • Patient has multifocal disease, , or extracranial .
  • Patient has a abnormal , including those where is determined by the Fridericia formula (QTcF >450 msec for males and >470 msec for females); and/or the patient has a history of Torsade de Pointes.
  • Patient is known to have dysphagia, short-gut syndrome, gastroparesis, or other condition that may limit the ingestion or gastrointestinal absorption of drugs administered orally.
  • Patient is known to have active Crohn's or other inflammatory bowel disease.
  • A history of other for which all treatment was completed at least 2 years before Day 1 and the patient has no evidence of disease. Exceptions include non-melanoma skin cancer, cervical carcinoma in situ, and superficial bladder cancer that has been removed or curatively treated.
  • On active treatment for other, unrelated malignancy or currently receiving any other agents.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to DSP-0390.
  • Patient has taken concurrent use of prohibited medications: carbamazepine, phenytoin, phenobarbital, and other strong or moderate inhibitors or inducers, and strong CYP2D6 inhibitors within 1 week or 5 half-lives (whichever is greater) prior to Day 1 or expects to use them during the study. Note both oral and IV ondansetron at doses ≤ 8mg q6 hours are permitted.
  • The presence of any active retinal abnormality determined by screening ophthalmologic examination.
  • Patient has significant cardiovascular disease, including (NYHA) Class III or IV congestive heart failure, myocardial infarction, unstable angina, pectoris, clinically significant cardiac arrhythmias, or stroke in the preceding 6 months prior to Day 1.
  • Uncontrolled intercurrent illness including, but not limited to, psychiatric illness/social situations that would limit compliance with study requirements, disorders associated with significant state, or ongoing or active infection.
  • Pregnant and/or breastfeeding. Women of must have a negative serum pregnancy test within 7 days prior to the first dose of DSP-0390.
  • Patients with are eligible unless their are \<350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended, as long as the ART agents do not fall under exclusion #8.
  • Patient has a known detectable viral load for , or evidence of a surface antigen.
  • Patient has had a major non-neurologic surgical procedure, surgical resection, open , or significant traumatic injury within 4 weeks prior to Day 1 or anticipates needing a major surgical procedure during the course of the study.
  • Patient has had a minor surgical procedure, fine needle aspirations, or core biopsies within 7 days prior to Day 1.
  • Patient has received chemotherapy or investigational anticancer therapy within 4 weeks (except 6 weeks for nitrosoureas and immunotherapy, or 8 weeks for an implanted nitrosoureas wafer) prior to Day 1.
  • Patient has had radiotherapy within 12 weeks prior to Day 1, unless relapse is confirmed by tumor biopsy.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Arm A Low Grade Gliomas: DSP-0390 120 mg

    Patients will be assigned to DSP-0390 120 mg once daily by mouth for approximately 2 weeks and up to 17 days prior to surgical resection, with the final dose being administered the morning of surgery.

  • Experimental
    Arm B High Grade Gliomas: DSP-0390 180 mg

    Patients will be assigned to DSP-0390 180 mg once daily by mouth for approximately 1 week prior to surgical resection, with the final dose being administered the morning of surgery.

Interventions

  • DSP-0390 will be administered orally with preferably 200 mL of water, or approximately one-half cup water. The patient will take DSP-0390 after a minimum of a 6-hour fast and will fast for 1 hour after taking the dose.

06

What researchers measure

Primary outcomes

  1. Unbound DSP-0390 concentration in non-enhancing tumor tissue

    Unbound DSP-0390 concentration in non-enhancing tumor tissue will be quantified using tissue removed during resection after treatment.

    Time frame: At time of surgery following treatment (estimated to be 2 weeks)

  2. Changes in DSP-0390 concentration in plasma

    Unbound DSP-0390 concentration in plasma will be quantified using blood samples taken throughout treatment.

    Time frame: From start of treatment through end of treatment (estimated to be 2 weeks)

Secondary outcomes

  1. Incidence of treatment emergent adverse events (TEAEs)

    Assessed using CTCAE v5.0

    Time frame: From start of treatment through 30 day follow-up (estimated to be 6 weeks)

  2. Incidence of grade 3 or higher study drug related adverse events (AEs)

    Assessed using CTCAE v5.0

    Time frame: From start of treatment through 30 day follow-up (estimated to be 6 weeks)

  3. Lathosterol levels in non-enhancing tumor tissue

    Lathosterol levels in non-enhancing tumor tissue will be quantified using tissue removed during resection after treatment.

    Time frame: At time of surgery following treatment (estimated to be 2 weeks)

  4. Changes in lathosterol levels in non-enhancing tumor tissue

    Lathosterol levels in non-enhancing tumor tissue will be quantified using tissue removed during resection after treatment.

    Time frame: Baseline and at time of surgery following treatment (estimated to be 2 weeks)

  5. Zymostenol levels in non-enhancing tumor tissue

    Zymostenol levels in non-enhancing tumor tissue will be quantified using tissue removed during resection after treatment.

    Time frame: At time of surgery following treatment (estimated to be 2 weeks)

  6. Changes in zymostenol levels in non-enhancing tumor tissue

    Zymostenol levels in non-enhancing tumor tissue will be quantified using tissue removed during resection after treatment.

    Time frame: Baseline and at time of surgery following treatment (estimated to be 2 weeks)

  7. Lathosterol/zymostenol (L/Z) ratio in non-enhancing tumor tissue

    L/Z ratio in non-enhancing tumor tissue will be quantified using tissue removed during resection after treatment.

    Time frame: At time of surgery following treatment (estimated to be 2 weeks)

  8. Changes in lathosterol/zymostenol (L/Z) ratio in non-enhancing tumor tissue

    L/Z ratio in non-enhancing tumor tissue will be quantified using tissue removed during resection after treatment.

    Time frame: Baseline and at time of surgery following treatment (estimated to be 2 weeks)

  9. Changes in lathosterol levels in blood

    Change in lathosterol levels in blood will be quantified after 5 days of DSP-0390 dosing.

    Time frame: From start of treatment through 5 days of treatment

  10. Changes in lathosterol levels in blood

    Change in lathosterol levels in blood will be quantified after 10 days of DSP-0390 dosing.

    Time frame: From start of treatment through 10 days of treatment

  11. Changes in lathosterol levels in blood

    Change in lathosterol levels in blood will be quantified after 11 days of DSP-0390 dosing.

    Time frame: From start of treatment through 11 days of treatment

  12. Changes in lathosterol levels in blood

    Change in lathosterol levels in blood will be quantified after 15 days of DSP-0390 dosing.

    Time frame: From start of treatment through day 15

  13. Changes in lathosterol levels in blood

    Change in lathosterol levels in blood will be quantified after surgical resection.

    Time frame: From start of treatment through day 16

  14. Changes in zymostenol levels in blood

    Change in zymostenol levels in blood will be quantified after 5 days of DSP-0390 dosing.

    Time frame: From start of treatment through 5 days of treatment

  15. Changes in zymostenol levels in blood

    Change in zymostenol levels in blood will be quantified after 10 days of DSP-0390 dosing.

    Time frame: From start of treatment through 10 days of treatment

  16. Changes in zymostenol levels in blood

    Change in zymostenol levels in blood will be quantified after 11 days of DSP-0390 dosing.

    Time frame: From start of treatment through 11 days of treatment

  17. Changes in zymostenol levels in blood

    Change in zymostenol levels in blood will be quantified after 15 days of DSP-0390 dosing.

    Time frame: From start of treatment through day 15

  18. Changes in zymostenol levels in blood

    Change in zymostenol levels in blood will be quantified after surgical resection.

    Time frame: From start of treatment through day 16

  19. Changes in L/Z ratio in blood

    Change in L/Z ratio in blood will be quantified after 5 days of DSP-0390 dosing.

    Time frame: From start of treatment through 5 days of treatment

  20. Changes in L/Z ratio in blood

    Change in L/Z ratio in blood will be quantified after 10 days of DSP-0390 dosing.

    Time frame: From start of treatment through 10 days of treatment

  21. Changes in L/Z ratio in blood

    Change in L/Z ratio in blood will be quantified after 11 days of DSP-0390 dosing.

    Time frame: From start of treatment through 11 days of treatment

  22. Changes in L/Z ratio in blood

    Change in L/Z ratio in blood will be quantified after 15 days of DSP-0390 dosing.

    Time frame: From start of treatment through day 15

  23. Changes in L/Z ratio in blood

    Change in L/Z ratio in blood will be quantified after surgical resection.

    Time frame: From start of treatment through day 16

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Omar H Butt, M.D., Ph.D. · Contactomarhbutt@wustl.edu · 314-747-4241
    • Omar H Butt, M.D., Ph.D. · Principal investigator
    • Ryan Cleary, M.D. · Sub investigator
    • Albert H Kim, M.D., Ph.D. · Sub investigator
    • Jingqin (Rosy) Luo, Ph.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication.

Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.

Of 166 non-industry phase 1 interventional studies under Glioma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's planned 24 months is below that.

Counting every sponsor, half of 213 studies reached it within 59 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2024
First posted
Oct 10, 2024
StartActual
Apr 3, 2025
Primary completionEst.
Apr 17, 2027
CompletionEst.
May 17, 2027
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06636162
Collaborators
Sumitomo Pharma America, Inc., The Foundation for Barnes-Jewish Hospital
Responsible party
Sponsor
First posted
Oct 10, 2024
Start date
Apr 3, 2025
Primary completion
Apr 17, 2027 (estimated)
Completion
May 17, 2027 (estimated)
Last update
May 6, 2026

Study contacts

Omar H Butt, M.D., Ph.D.
Contact
omarhbutt@wustl.edu
314-747-4241
Omar H Butt, M.D., Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DSP-0390

Start the discussion